In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synvista Therapeutics Inc.

www.synvista.com

Latest From Synvista Therapeutics Inc.

The Genomics of Longevity

A group of drug discovery companies believes it has found a way to use scientific discoveries about the genetics of aging to develop novel drugs for specific diseases. These companies begin with insights from animal models of longevity and long-lived human populations, which they hope will help them discover new targets for age-related diseases. Several companies have rallied around calorie restriction, an intervention known to increase lifespan in laboratory animals, and are characterizing genetic and phenotypic changes associated with calorie restriction. Others believe they have found key genes that regulate aging, and hope to use this knowledge to develop drugs for such age-related as diseases as cardiovascular disease, stroke, cancer, and diabetes. The challenges for companies will be to validate mechanisms implicated in aging, and then link them to specific diseases. However, the diseases of aging are some of the toughest drug development categories; they're often progressive diseases that develop over the course of years, and proving that drugs slow down disease progression or prevent onset involves tough endpoints.
BioPharmaceutical Platform Technologies

Rademacher Group LTD

Scientists at Rademacher Group are trying to elucidate the molecular mechanisms of glucose control.
BioPharmaceutical

Let Them Eat Cake

European governments are trying to have it both ways: they're encouraging the creation-by-merger of large national companies at the same time they're trying to create national biotech industries. But biotechs need more companies to do deals with--not fewer. And the larger the companies that the mergers create, the more likely the new megafirms will turn to American biotechs for their deals.
BioPharmaceutical Business Strategies

Such a Deal, Late-Phase

The cliché is that late-stage deals are necessarily expensive. Genentech is showing they don't have to be, lowering its cost of access to drugs by weighting most of its payments towards equity and milestones--and buying the drugs others pass over as too risky.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Inflammation
  • Metabolic Disorders
  • Alias(es)
  • Alteon Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Synvista Therapeutics Inc.
  • Senior Management
  • Noah Berkowitz, MD, Pres. & CEO
    Carl M Mendel, MD, VP, Clin. Dev. & CMO
    Elizabeth A O'Dell, VP, Fin. & Admin.
    David Tantillo, Senior Dir., Mktg. & Sales
  • Contact Info
  • Synvista Therapeutics Inc.
    Phone: (201) 934-5000
    221 West Grand Ave.
    Montvale, NJ 07645
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register